Protection of Blood Brain Barrier Integrity and Modulation of Inflammatory Mediators During Treatment of Pneumococcal Meningitis with Daptomycin or Ceftriaxone

ISSN: 1875-5739 (Online)
ISSN: 1567-2026 (Print)


Volume 11, 4 Issues, 2014


Download PDF Flyer




Current Neurovascular Research

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 74th of 194 in Clinical Neurology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Prof. Kenneth Maiese
Neurology and Neurosciences UMDNJ
205 South Orange Avenue, F1220
Newark, NJ 07101
USA
Email: wntin75@yahoo.com

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.735
5 - Year: 2.835

Protection of Blood Brain Barrier Integrity and Modulation of Inflammatory Mediators During Treatment of Pneumococcal Meningitis with Daptomycin or Ceftriaxone

Author(s): Tatiana Barichello, Joao Carlos Nepomuceno Goncalves, Jaqueline da Silva Generoso, Lutiana Roque Simoes, Michael Hikaru Tashiro, Jessica de Assis Goularte, Francieli Vuolo, David Henrique Rodrigues, Marcia Carvalho Vilela, Fabricia Petronilho, Antonio Lucio Teixeira and Joao Quevedo

Affiliation: Laboratorio de Microbiologia Experimental, PPGCS, UNASAU, Universidade do Extremo Sul Catarinense, 88806-000 Criciúma, SC, Brazil.

Abstract

Pneumococcal meningitis is associated with neurologic sequelae, such as learning and memory impairment. Most recently, a nonbacteriolytic antibiotic has been investigated to minimise the inflammatory host response and prevent cognitive damage. In this study, we compared daptomycin (DPTO) or ceftriaxone (CFX) treatment on the inflammatory parameters and on the blood-brain barrier (BBB) integrity in experimental pneumococcal meningitis. In the first experiment, the animals received 10 µl of a Streptococcus pneumoniae suspension or artificial cerebrospinal fluid by intracerebroventricular (i.c.v.) and were treated with CFX or DPTO at 18 h post-infection. The animals were euthanised at 18, 20, 24, 36 and 40 h post-infection. In the hippocampus, brain-derived neurotrophic factor (BDNF), tumour necrosis factor alpha (TNF-α ), interleukin-6 (IL-6) and IL-10 levels were not different between treatment groups; however, IL-4 and cytokine-induced neutrophil chemoattractant 1 (CINC-1) levels decreased in the CFX group. In the frontal cortex, TNF- α, IL- 4, IL-6, IL-10 and BDNF levels were not different between treatment groups. Only CINC-1 levels decreased at 40 h postinfection with CFX treatment. In the second experiment, the animals received DPTO or CFX for 7 days and were euthanised 10 days after pneumococcal meningitis induction. TNF-α , IL-6, IL-10, CINC-1 and BDNF levels were not different between treatment groups in the hippocampus; however, IL-4 levels decreased in CFX group. In the third experiment, the animals received 10 µ l of an S. pneumoniae suspension or artificial CSF by i.c.v. and were treated with a single dose of CFX or DTPO antibiotic; assessment of the BBB breakdown showed that both antibiotics prevented the BBB disruption. Both treatments equally protected the BBB integrity, and there were no significant difference in cytokine production.

Keywords: BDNF, ceftriaxone, cytokine, daptomycin, meningitis, streptococcus pneumonia.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 11
Issue Number: 3
First Page: 210
Last Page: 222
Page Count: 13
DOI: 10.2174/1567202611666140520123424
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science